Formulation and Specifications: Tablets: 100mg, 150mg
Indications: Locally advanced or metastatic NSCLC with sensitive mutations in the EGFR gene.
Key points for rational drug use:
1. EGFR-sensitive mutations detected by EGFR gene testing methods approved by the State Drug Administration must be clearly available before drug administration.
2. Patients with NSCLC with EGFR gene mutations with brain metastases and patients with exon 21 L858R substitution mutation-positive advanced NSCLC can be treated with erlotinib in combination with bevacizumab.
3. The recommended dose of erlotinib alone for NSCLC is 150 mg/d, taken at least 1 hour before or 2 hours after a meal.
4. Common skin mucosal reactions and diarrhea must be noted during drug administration. Special attention should be paid to the occurrence of interstitial pneumonia, abnormal liver function and ocular symptoms.
5. Avoid combination with strong inhibitors of CYP3A4 or strong inducers. Avoid combining erlotinib with drugs that significantly and consistently raise the pH of gastric juice.
6. Smoking leads to lower exposure to erlotinib and patients are advised to quit smoking.
*7. Erlotinib is approved by the US FDA in combination with gemcitabine for the first-line treatment of locally advanced, unresectable or metastatic pancreatic cancer. This indication is not yet approved in China and may be used with adequate communication with the patient. The dosing is l00mg once daily.